51. Interferon-Beta Treatment Differentially Alters TLR2 and TLR4-Dependent Cytokine Production in Multiple Sclerosis Patients.
- Author
-
Oliveira IBN, Gomes RS, Gomides LF, Dos Santos JC, Carneiro MAD, Ribeiro-Dias F, and Diniz DS
- Subjects
- Adult, Cytokines biosynthesis, Cytokines drug effects, Female, Humans, Immunologic Factors therapeutic use, Male, Middle Aged, Multiple Sclerosis drug therapy, Toll-Like Receptor 2 immunology, Toll-Like Receptor 4 immunology, Interferon-beta therapeutic use, Interleukin-10 biosynthesis, Multiple Sclerosis immunology, Tumor Necrosis Factor-alpha biosynthesis, Tumor Necrosis Factor-alpha drug effects
- Abstract
Objective: Multiple sclerosis (MS) is a multifactorial chronic disease that affects the central nervous system (CNS). Toll-like receptors (TLRs) play a central role in cytokine production after pathogen- and danger-associated molecular patterns (PAMPs and DAMPs) and contribute to CNS damage in MS patients. Here, we evaluated the effects of interferon (IFN)-β treatment in TLR2 and TLR4-dependent cytokine production and mRNA expression in whole-blood cell cultures from MS patients., Methods: We evaluated cytokine production by ELISA from whole-blood cell culture supernatants and mRNA expression by real-time polymerase chain reaction in peripheral blood mononuclear cells (PBMCs)., Results: In patients treated with IFN-β, tumor necrosis factor (TNF)-α production after exposure to TLR2 agonist (Pam3Cys) was lower than in healthy controls and untreated MS patients. However, IFN-β treatment had no significant effect on TNF-α production after TLR4 agonist (LPS) stimulation. On the other hand, interleukin (IL)-10 production was increased in TLR4- but not in TLR2-stimulated whole-blood cell culture from MS patients under IFN-β treatment when compared to the controls. No differences in TNF-α or IL-10 mRNA expression in PBMCs from healthy controls and untreated or treated MS patients were detected, although PBMCs from treated patients presented higher levels of IL-32γ mRNA than those from controls., Conclusions: Our data suggest that IFN-β treatment alters the TLR-dependent immune response of PBMCs from MS patients. This may contribute to the beneficial effects of IFN-β treatment., (© 2019 S. Karger AG, Basel.)
- Published
- 2019
- Full Text
- View/download PDF